Changes in mammographic density over time and the risk of breast cancer: An observational cohort study.


Journal

Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 01 02 2019
revised: 16 04 2019
accepted: 26 04 2019
pubmed: 28 5 2019
medline: 15 1 2020
entrez: 28 5 2019
Statut: ppublish

Résumé

The effect of changes in mammographic density over time on the risk of breast cancer remains inconclusive. We used information from four centres of the Breast Cancer Screening Program in Spain in the period 1996-2015. We analysed individual level data from 117,388 women first screened age 50-54, with at least two screening examinations. Breast density was determined using the BI-RADS classification (A to D in increasing order) at earliest and latest screening examination. Adjusted Poisson regression models were used to estimate the relative risk (RR) and 95% confidence intervals (95%CI) of the association between changes in mammographic density and breast cancer risk over time. During an average 5.8 years of follow-up, 1592 (1.36%) women had a breast cancer diagnosis. An increase in density category increased breast cancer risk, and a decrease in density decreased the risk, compared with women who remained in the same BI-RADS category. Women whose density category increased from B to C or B to D had a RR of 1.55 (95%CI = 1.24-1.94) and 2.32 (95%CI = 1.48-3.63), respectively. The RR for women whose density increased from C to D was 1.51 (95%CI = 1.03-2.22). Changes in BI-RADS density were similarly associated with the risk for invasive cancer than for ductal carcinoma in situ. Although a modest proportion of women changed BI-RADS density category, mammographic density changes modulated the risk of breast cancer and identified women at a differential risk. Using two longitudinal measures of BI-RADS density could help target women for risk-based screening strategies.

Sections du résumé

BACKGROUND BACKGROUND
The effect of changes in mammographic density over time on the risk of breast cancer remains inconclusive.
METHODS METHODS
We used information from four centres of the Breast Cancer Screening Program in Spain in the period 1996-2015. We analysed individual level data from 117,388 women first screened age 50-54, with at least two screening examinations. Breast density was determined using the BI-RADS classification (A to D in increasing order) at earliest and latest screening examination. Adjusted Poisson regression models were used to estimate the relative risk (RR) and 95% confidence intervals (95%CI) of the association between changes in mammographic density and breast cancer risk over time.
RESULTS RESULTS
During an average 5.8 years of follow-up, 1592 (1.36%) women had a breast cancer diagnosis. An increase in density category increased breast cancer risk, and a decrease in density decreased the risk, compared with women who remained in the same BI-RADS category. Women whose density category increased from B to C or B to D had a RR of 1.55 (95%CI = 1.24-1.94) and 2.32 (95%CI = 1.48-3.63), respectively. The RR for women whose density increased from C to D was 1.51 (95%CI = 1.03-2.22). Changes in BI-RADS density were similarly associated with the risk for invasive cancer than for ductal carcinoma in situ.
CONCLUSIONS CONCLUSIONS
Although a modest proportion of women changed BI-RADS density category, mammographic density changes modulated the risk of breast cancer and identified women at a differential risk. Using two longitudinal measures of BI-RADS density could help target women for risk-based screening strategies.

Identifiants

pubmed: 31132476
pii: S0960-9776(19)30494-1
doi: 10.1016/j.breast.2019.04.007
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

108-115

Investigateurs

Andrea Burón (A)
Xavier Castells (X)
Laia Domingo (L)
Javier Louro (J)
Margarita Posso (M)
Ana Rodríguez-Arana (A)
Marta Román (M)
Maria Sala (M)
Sònia Servitja (S)
Mar Vernet (M)
Xavier Andreu (X)
Marisa Baré (M)
Llucia Benito (L)
Carmen Vidal (C)
María Jesús Quintana (MJ)
Judit Solà-Roca (J)
Mar Sánchez (M)
Miguel Prieto (M)
Jaume Galceran (J)
Francina Saladié (F)
Joana Ferrer (J)
Josep Alfons Espinàs (JA)
Lupe Peñalva (L)
Isabel Torá-Rocamora (I)
Xavier Bargalló (X)

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Marta Román (M)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Maria Sala (M)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Marisa Baré (M)

Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain; Clinical Epidemiology and Cancer Screening, Parc Taulí University Hospital, Sabadell, Spain.

Margarita Posso (M)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Carmen Vidal (C)

Cancer Prevention and Monitoring Program, Catalan Institute of Oncology, Barcelona, Spain.

Javier Louro (J)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain.

Mar Sánchez (M)

General Directorate of Public Health, Government of Cantabria, Santander, Spain.

Lupe Peñalva (L)

Breast Cancer Screening Technical Office. Private Foundation Asil Hospital, Granollers, Spain.

Xavier Castells (X)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain. Electronic address: xcastells@parcdesalutmar.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH